Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer
Journal of Medical Imaging and Radiation Oncology · 2024
DOI: 10.1111/1754-9485.13639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2024. Verfasst von Tae Hoon Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Radiation Dose Hypofractionation, Prostate-Specific Antigen. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study aimed to analyse the treatment outcomes of moderately hypofractionated radiation therapy (RT) combined with androgen deprivation therapy (ADT) and the prognostic implications of prostate‐specific antigen (PSA) kinetics in high‐risk localized prostate cancer.
Methods
The medical records of 140 patients who underwent definitive RT (70 Gy in 28 fractions) combined with ADT were retrospectively reviewed. ADT consists of a gonadotropin‐releasing hormone agonist and an anti‐androgen. Clinical outcomes included the biochemical failure rate (BFR), clinical failure rate (CFR), overall survival (OS) and prostate cancer–specific survival (PCSS). The BFR and CFR were stratified by the PSA nadir and the time to the PSA nadir, respectively. Acute and late genitourinary and gastrointestinal adverse events were also recorded.
Results
The 5‐year BFR, CFR, OS and PCSS rates were 9.8%, 4.5%, 90.2% and 98.7%, respectively. Ninety‐five (67.9%) patients achieved a PSA nadir of 0.01 ng/mL. Patients with a PSA nadir >0.01 ng/mL had a significantly higher BFR and CFR (BFR, P = 0.001; CFR, P = 0.027), even after adjusting for other prognostic factors [per 0.1 ng/mL; BFR, hazard ratio (HR) 4.440, P < 0.001; CFR, HR 4.338, P = 0.001]. However, the time to the PSA nadir and pre‐RT PSA were not significantly associated with the BFR and CFR. Six patients (4.3%) reported grade 3 late adverse events, mostly haematuria and haematochezia.
Conclusion
Definitive RT with moderate hypofractionation combined with long‐term ADT showed good efficacy for high‐risk localized prostate cancer. The lowest PSA nadir was significantly associated with a low recurrence rate, indicating the importance of PSA follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Radiation Oncology, Chungbuk National University Hospital, Cheongju, Korea.
- Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Radiation Oncology, Kyungpook National University Chilgok Hospital, Daegu, Korea.
ORCID-Profile: Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Bong Kyung Bae, Won Park
Zitieren
APA
Lee, T. H., Pyo, H., Yoo, G. S., Jeon, S. S., Seo, S. I., Jeong, B. C., Jeon, H. G., Sung, H. H., Kang, M., Song, W., Chung, J. H., Bae, B. K., & Park, W. (2024). Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.13639
Vancouver
Lee TH, Pyo H, Yoo GS, Jeon SS, Seo SI, Jeong BC, et al. Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer. Journal of Medical Imaging and Radiation Oncology. 2024. doi:10.1111/1754-9485.13639
BibTeX
@article{Lee2024,
author = {Lee, Tae Hoon and Pyo, Hongryull and Yoo, Gyu Sang and Jeon, Seong Soo and Seo, Seong Il and Jeong, Byong Chang and Jeon, Hwang Gyun and Sung, Hyun Hwan and Kang, Minyong and Song, Wan and Chung, Jae Hoon and Bae, Bong Kyung and Park, Won},
title = {Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2024},
doi = {10.1111/1754-9485.13639}
}
EUVIMED